or Try an Advanced Search...

    Regeneron Stocks List

    Symbol Grade Name % Change
    ADVM D Adverum Biotechnologies, Inc. -0.50
    SNY D Sanofi 0.92
    REGN F Regeneron Pharmaceuticals, Inc. 0.96
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development

    Related ETFs - A few ETFs which own one or more of the above listed Regeneron stocks.

    Symbol Grade Name Weight
    VIRS A Pacer BioThreat Strategy ETF 9.41
    PINK D Simplify Health Care ETF 9.08
    IBBQ B Invesco Nasdaq Biotechnology ETF 7.53
    BBH D Market Vectors Biotech ETF 7.13
    IBB B iShares Nasdaq Biotechnology Index Fund 5.89
    View all Regeneron ETFs...
    Compare ETFs
    Compare IBBQ to IBB Compare PINK to IBBQ Compare VIRS to IBB

        Regeneron Stocks Recent News

        Date Stock Title
        Nov 7 REGN Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer
        Nov 7 SNY Advent Mulls €5 Billion Sale of Generic Drugmaker Zentiva
        Nov 7 SNY EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
        Nov 7 REGN EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
        Nov 6 REGN Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
        Nov 6 SNY Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
        Nov 6 REGN Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
        Nov 6 SNY Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
        Nov 5 REGN Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
        Nov 5 SNY Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
        Nov 5 REGN Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
        Nov 4 ADVM Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
        Nov 4 ADVM Adverum Biotechnologies GAAP EPS of -$1.30 beats by $0.01
        Nov 4 ADVM Adverum Biotechnologies: Q3 Earnings Snapshot
        Nov 4 ADVM Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
        Nov 4 REGN Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
        Nov 2 REGN Regeneron price target lowered to $1,126 from $1,137 at Truist
        Nov 1 SNY Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
        Nov 1 SNY Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
        Nov 1 REGN What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development
        Regeneron

        Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Eastview, near Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

        More about Regeneron
        Browse All Tags